MRM Health raises 14 million euros for the development of microbiome-based medicines

MRM Health, a new spin-off from MRM Technologies, VIB, KU Leuven and UGent, is entering into its first industrial partnership with DuPont Nutrition & Biosciences in the field of metabolic diseases.

MRM Health nv, a biopharmaceutical company focused on the development of innovative treatments based on the human microbiome, has announced that it will collaborate with DuPont Nutrition & Biosciences. The new company also successfully completed a first external investment round in which Ackermans & van Haaren, DuPont Nutrition & Biosciences, MRM Technologies, Qbic II and VIB participated. MRM Health and DuPont Nutrition & Biosciences join forces to tackle a number of metabolic diseases. By combining the MRM Health technology platform and selected DuPont strains, new treatments will be developed based on living bacterial strains. MRM Health was incorporated into MRM Technologies through a partial split of the activities of ProDigest, an international specialist in bowel and microbiome research. In this way, ProDigest can continue and expand its independent and unique services related to scientific research to customers in the pharmaceutical, food and feed industries. These activities are based on the SHIME technology (Simulator of the Human Intestinal Microbial Ecosystem, unique laboratory models of the digestive system in humans and animals) from ProDigest, which can be used to simulate the metabolism and bio-distribution of developing pharmaceutical products, as well as the interaction of the gut microbiome with pharmaceutical products, food ingredients, animal feed and health products.